|
|
|
0 members (),
1,680
guests, and
26
robots. |
|
Key:
Admin,
Global Mod,
Mod
|
|
S |
M |
T |
W |
T |
F |
S |
|
|
|
|
|
1
|
2
|
3
|
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
|
11
|
12
|
13
|
14
|
15
|
16
|
17
|
|
18
|
19
|
20
|
21
|
22
|
23
|
24
|
|
25
|
26
|
27
|
28
|
29
|
30
|
31
|
|
There are no members with birthdays on this day. |
Volcano earthquake report for Thursday, 22 October 2026
• M 3.0 - 3 km W of Columbia City, Oregon
• M 4.1 - 65 km NE of Tadine, New Caledonia
• M 2.1 - 126 km WSW of Adak, Alaska
• M 1.5 - 26 km E of Honaunau-Napoopoo, Hawaii
• M 2.2 - 69 km SW of Nanwalek, Alaska
|
#322666
Thu 06 Aug 2015 05:32:PM
|
Joined: Feb 2001
Posts: 678,977
Launch Director
|
|
Launch Director
Joined: Feb 2001
Posts: 678,977 |
Results of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL) – a rare type of non-Hodgkin lymphoma that affects the skin. Currently, there is no cure for CTCL aside from a bone marrow transplant. However, the new study shows that the topical gel can eliminate malignant T cells, leading to diminished lesions. Source: Topical gel proves safe, effective treatment for patients with skin t cell lymphoma
David Cottle
UBB Owner & Administrator
|
|
CMS The Best Conveyancing solicitors conveyancing quotes throughout the UK
For any webhosting enquiries please email webmaster@aus-city.com
|
|
Forums60
Topics889,200
Posts923,997
Members2,960
| |
Most Online102,106 Jul 10th, 2026
|
|
|
|
|
|